Literature DB >> 11398078

Expression of the high-affinity IgE receptor on peripheral blood dendritic cells: differential binding of IgE in atopic asthma.

J A Holloway1, S T Holgate, A E Semper.   

Abstract

BACKGROUND: Dendritic cells can express the high-affinity IgE receptor (FcepsilonRI), which, in the presence of specific IgE, facilitates the uptake of allergen, leading to increased activation of allergen-specific T cells. FcepsilonRI expression by dendritic cells is higher in the airways of atopic asthmatic subjects than in those of healthy, nonatopic control subjects.
OBJECTIVE: The aims of this study were to determine whether a similar difference in FcepsilonRI expression occurs between dendritic cells in the peripheral blood of atopic asthmatic subjects and healthy individuals and also whether an altered ability of FcepsilonRI(+) peripheral blood dendritic cells to bind IgE accompanies the atopic asthmatic state.
METHODS: Flow cytometry was used to analyze the surface expression of FcepsilonRI and exogenously bound IgE on dendritic cells identified as lineage negative (CD3, CD14, CD16, CD19, and CD56) and HLA-DR bright.
RESULTS: The total expression of FcepsilonRI on the surface of dendritic cells from healthy and asthmatic subjects was not significantly different. However, in vivo, dendritic cells from atopic asthmatic subjects had higher levels of receptor occupancy by IgE and bound exogenous IgE in vitro more efficiently than dendritic cells from healthy subjects.
CONCLUSION: The similar levels of expression of FcepsilonRI on peripheral blood dendritic cells from healthy and asthmatic subjects suggest that the local environment in the airway is responsible for the upregulation of surface FcepsilonRI on airway dendritic cells in asthma. The results also suggest that the functional ability of FcepsilonRI to bind IgE is differentially controlled in the atopic state.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398078     DOI: 10.1067/mai.2001.115039

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

1.  Adoptive transfer of dendritic cells from allergic mice induces specific immunoglobulin E antibody in naïve recipients in absence of antigen challenge without altering the T helper 1/T helper 2 balance.

Authors:  Stephen J Chambers; Eugenio Bertelli; Mark S Winterbone; Mari Regoli; Angela L Man; Claudio Nicoletti
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

Review 2.  Omalizumab for severe asthma: efficacy beyond the atopic patient?

Authors:  Christian Domingo
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 3.  The immunoglobulin E receptor: expression and regulation.

Authors:  Edward R Conner; Sarbjit S Saini
Journal:  Curr Allergy Asthma Rep       Date:  2005-05       Impact factor: 4.919

4.  A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.

Authors:  Gennaro D'Amato; Antonello Salzillo; Amedeo Piccolo; Maria D'Amato; Gennaro Liccardi
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

5.  Dendritic cell-bound IgE functions to restrain allergic inflammation at mucosal sites.

Authors:  B Platzer; K Baker; M P Vera; K Singer; M Panduro; W S Lexmond; D Turner; S O Vargas; J-P Kinet; D Maurer; R M Baron; R S Blumberg; E Fiebiger
Journal:  Mucosal Immunol       Date:  2014-09-17       Impact factor: 7.313

Review 6.  Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review.

Authors:  Gennaro D'Amato; Anna Stanziola; Alessandro Sanduzzi; Gennaro Liccardi; Antonello Salzillo; Carolina Vitale; Antonio Molino; Alessandro Vatrella; Maria D'Amato
Journal:  Multidiscip Respir Med       Date:  2014-04-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.